Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation

Objective: Transient receptor potential canonical 5 (TRPC5) is functionally expressed on a range of cells including fibroblast-like synoviocytes, which play an important role in arthritis. A role for TRPC5 in inflammation has not been previously shown in vivo. We investigated the contribution of TRP...

Full description

Bibliographic Details
Main Authors: Alawi, Khadija M., Russell, Fiona A., Aubdool, Aisah A., Srivastava, Salil, Riffo-Vasquez, Yanira, Baldissera, Lineu, Thakore, Pratish, Saleque, Nurjahan, Fernandes, Elisabeth S., Walsh, David A., Brain, Susan D.
Format: Article
Published: BMJ Publishing Group 2017
Online Access:https://eprints.nottingham.ac.uk/51913/
_version_ 1848798602187505664
author Alawi, Khadija M.
Russell, Fiona A.
Aubdool, Aisah A.
Srivastava, Salil
Riffo-Vasquez, Yanira
Baldissera, Lineu
Thakore, Pratish
Saleque, Nurjahan
Fernandes, Elisabeth S.
Walsh, David A.
Brain, Susan D.
author_facet Alawi, Khadija M.
Russell, Fiona A.
Aubdool, Aisah A.
Srivastava, Salil
Riffo-Vasquez, Yanira
Baldissera, Lineu
Thakore, Pratish
Saleque, Nurjahan
Fernandes, Elisabeth S.
Walsh, David A.
Brain, Susan D.
author_sort Alawi, Khadija M.
building Nottingham Research Data Repository
collection Online Access
description Objective: Transient receptor potential canonical 5 (TRPC5) is functionally expressed on a range of cells including fibroblast-like synoviocytes, which play an important role in arthritis. A role for TRPC5 in inflammation has not been previously shown in vivo. We investigated the contribution of TRPC5 in arthritis. Methods: Male wild-type and TRPC5 knockout (KO) mice were used in a complete Freund’s adjuvant (CFA)-induced unilateral arthritis model, assessed over 14 days. Arthritis was determined by measurement of knee joint diameter, hindlimb weightbearing asymmetry and pain behaviour. Separate studies involved chronic pharmacological antagonism of TRPC5 channels. Synovium from human post-mortem control and inflammatory arthritis samples were investigated for TRPC5 gene expression. Results: At baseline, no differences were observed. CFA-induced arthritis resulted in increased synovitis in TRPC5 KO mice assessed by histology. Additionally, TRPC5 KO mice demonstrated reduced ipsilateral weightbearing and nociceptive thresholds (thermal and mechanical) following CFA-induced arthritis. This was associated with increased mRNA expression of inflammatory mediators in the ipsilateral synovium and increased concentration of cytokines in synovial lavage fluid. Chronic treatment with ML204, a TRPC5 antagonist, augmented weightbearing asymmetry, secondary hyperalgesia and cytokine concentrations in the synovial lavage fluid. Synovia from human inflammatory arthritis demonstrated a reduction in TRPC5 mRNA expression. Conclusions: Genetic deletion or pharmacological blockade of TRPC5 results in an enhancement in joint inflammation and hyperalgesia. Our results suggest that activation of TRPC5 may be associated with an endogenous anti-inflammatory/analgesic pathway in inflammatory joint conditions.
first_indexed 2025-11-14T20:22:23Z
format Article
id nottingham-51913
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:22:23Z
publishDate 2017
publisher BMJ Publishing Group
recordtype eprints
repository_type Digital Repository
spelling nottingham-519132020-05-04T18:33:00Z https://eprints.nottingham.ac.uk/51913/ Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation Alawi, Khadija M. Russell, Fiona A. Aubdool, Aisah A. Srivastava, Salil Riffo-Vasquez, Yanira Baldissera, Lineu Thakore, Pratish Saleque, Nurjahan Fernandes, Elisabeth S. Walsh, David A. Brain, Susan D. Objective: Transient receptor potential canonical 5 (TRPC5) is functionally expressed on a range of cells including fibroblast-like synoviocytes, which play an important role in arthritis. A role for TRPC5 in inflammation has not been previously shown in vivo. We investigated the contribution of TRPC5 in arthritis. Methods: Male wild-type and TRPC5 knockout (KO) mice were used in a complete Freund’s adjuvant (CFA)-induced unilateral arthritis model, assessed over 14 days. Arthritis was determined by measurement of knee joint diameter, hindlimb weightbearing asymmetry and pain behaviour. Separate studies involved chronic pharmacological antagonism of TRPC5 channels. Synovium from human post-mortem control and inflammatory arthritis samples were investigated for TRPC5 gene expression. Results: At baseline, no differences were observed. CFA-induced arthritis resulted in increased synovitis in TRPC5 KO mice assessed by histology. Additionally, TRPC5 KO mice demonstrated reduced ipsilateral weightbearing and nociceptive thresholds (thermal and mechanical) following CFA-induced arthritis. This was associated with increased mRNA expression of inflammatory mediators in the ipsilateral synovium and increased concentration of cytokines in synovial lavage fluid. Chronic treatment with ML204, a TRPC5 antagonist, augmented weightbearing asymmetry, secondary hyperalgesia and cytokine concentrations in the synovial lavage fluid. Synovia from human inflammatory arthritis demonstrated a reduction in TRPC5 mRNA expression. Conclusions: Genetic deletion or pharmacological blockade of TRPC5 results in an enhancement in joint inflammation and hyperalgesia. Our results suggest that activation of TRPC5 may be associated with an endogenous anti-inflammatory/analgesic pathway in inflammatory joint conditions. BMJ Publishing Group 2017-02-28 Article PeerReviewed Alawi, Khadija M., Russell, Fiona A., Aubdool, Aisah A., Srivastava, Salil, Riffo-Vasquez, Yanira, Baldissera, Lineu, Thakore, Pratish, Saleque, Nurjahan, Fernandes, Elisabeth S., Walsh, David A. and Brain, Susan D. (2017) Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation. Annals of the Rheumatic Diseases, 76 (1). pp. 252-260. ISSN 1468-2060 http://ard.bmj.com/content/76/1/252 doi:10.1136/annrheumdis-2015-208886 doi:10.1136/annrheumdis-2015-208886
spellingShingle Alawi, Khadija M.
Russell, Fiona A.
Aubdool, Aisah A.
Srivastava, Salil
Riffo-Vasquez, Yanira
Baldissera, Lineu
Thakore, Pratish
Saleque, Nurjahan
Fernandes, Elisabeth S.
Walsh, David A.
Brain, Susan D.
Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
title Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
title_full Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
title_fullStr Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
title_full_unstemmed Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
title_short Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
title_sort transient receptor potential canonical 5 (trpc5) protects against pain and vascular inflammation in arthritis and joint inflammation
url https://eprints.nottingham.ac.uk/51913/
https://eprints.nottingham.ac.uk/51913/
https://eprints.nottingham.ac.uk/51913/